Mark P Wentland
Overview
Explore the profile of Mark P Wentland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang J, VanAlstine M, Phillips J, Wentland M, Hough L
Acta Pharm Sin B
. 2014 Jul;
2(2):137-145.
PMID: 25068100
Cytochrome P450 (CYP)-mediated epoxidation of arachidonic acid (AA) contributes to important biological functions, including the pain-relieving responses produced by analgesic drugs. However, the relevant epoxygenase(s) remain unidentified. Presently, we describe...
2.
Hoerbelt P, Nalwalk J, Phillips J, Wentland M, Shan Z, Hough L
Eur J Pharmacol
. 2013 Jul;
714(1-3):464-71.
PMID: 23834775
Improgan, a non-opioid, antinociceptive drug, activates descending analgesic circuits following brain administration, but the improgan receptor remains unidentified. Since biotinylation of drugs can enhance drug potency or facilitate discovery of...
3.
VanAlstine M, Wentland M, Alvarez J, Cao Q, Cohen D, Knapp B, et al.
Bioorg Med Chem Lett
. 2013 Feb;
23(7):2128-33.
PMID: 23434225
Derivatives of the lead compound N-BPE-8-CAC (1) where each CH of the biphenyl group was individually replaced by N were prepared in hopes of identifying high affinity ligands with improved...
4.
Wentland M, Jo S, Gargano J, VanAlstine M, Cohen D, Bidlack J
Bioorg Med Chem Lett
. 2012 Nov;
22(24):7340-4.
PMID: 23142613
N-[2-(4'-methoxy[1,1'-biphenyl]-4-yl)ethyl]-8-CAC (1) is a high affinity (K(i)=0.084 nM) ligand for the μ opioid receptor and served as the lead compound for this study. Analogues of 1 were made in hopes...
5.
Porter D, Farmaki E, Altilia S, Schools G, West D, Chen M, et al.
Proc Natl Acad Sci U S A
. 2012 Aug;
109(34):13799-804.
PMID: 22869755
Conventional chemotherapy not only kills tumor cells but also changes gene expression in treatment-damaged tissues, inducing production of multiple tumor-supporting secreted factors. This secretory phenotype was found here to be...
6.
Hough L, Nalwalk J, Yang J, Conroy J, VanAlstine M, Yang W, et al.
Pain
. 2011 Feb;
152(4):878-887.
PMID: 21316152
The search for the mechanism of action of improgan (a nonopioid analgesic) led to the recent discovery of CC12, a compound that blocks improgan antinociception. Because CC12 is a cytochrome...
7.
Conroy J, Fang C, Gu J, Zeitlin S, Yang W, Yang J, et al.
Nat Neurosci
. 2010 Feb;
13(3):284-6.
PMID: 20139973
To assess the importance of brain cytochrome P450 (P450) activity in mu opioid analgesic action, we generated a mutant mouse with brain neuron-specific reductions in P450 activity; these mice showed...
8.
Wentland M, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, et al.
Bioorg Med Chem Lett
. 2009 Mar;
19(8):2289-94.
PMID: 19282177
A series of novel high affinity opioid receptor ligands have been made whereby the phenolic-OH group of nalbuphine, naltrexone methiodide, 6-desoxonaltrexone, hydromorphone and naltrindole was replaced by a carboxamido group...
9.
Wentland M, Lu Q, Ganorkar R, Zhang S, Jo S, Cohen D, et al.
Bioorg Med Chem Lett
. 2008 Dec;
19(2):365-8.
PMID: 19091564
A series of 7,8- and 8,9-fused triazole and imidazole analogues of cyclazocine have been made and characterized in opioid receptor binding and [(35)S]GTPgammaS assays. Target compounds were designed to explore...
10.
Wentland M, Lou R, Lu Q, Bu Y, VanAlstine M, Cohen D, et al.
Bioorg Med Chem Lett
. 2008 Nov;
19(1):203-8.
PMID: 19027293
A series of 15 novel opioid derivatives were made where the prototypic phenolic-OH group of traditional opioids was replaced by a carboxamido (CONH(2)) group. For 2,6-methano-3-benzazocines and morphinans similar or,...